What does the SLN analyst rating from Jefferies mean for shareholders?

A maintained Buy means Jefferies still prefers the stock versus peers. The SLN analyst rating signals value at the cited enterprise value but does not introduce a new price target. Shareholders should weigh pipeline risk and funding needs.

Did Jefferies set a new SLN price target with this SLN analyst rating?

No, Jefferies reiterated a Buy without a formal numeric price target. The note emphasized relative valuation at **$175M+ EV** rather than publishing a specific target for Silence Therapeutics plc.

How should I use the SLN analyst rating in portfolio decisions?

Use the SLN analyst rating as one input among many. Factor in the company’s **B** Meyka grade, market cap **$259,786,714**, cash runway, and upcoming clinical milestones before changing position sizes.

Where can I read the original analyst note referenced in the SLN analyst rating?

The Jefferies commentary is summarized on StreetInsider. Read the full note on StreetInsider for verbatim language and context [StreetInsider article](https://www.streetinsider.com/Analyst+Comments/Jefferies+Reiterates+Buy+Rating+on+Silence+Therapeutics+%28SLN%29%3A+%22looks+cheap+at+%24175M%2B+EV%2

Analyst Ratings

Jefferies Maintains Buy on SLN Silence Therapeutics plc March 2026

ByDanny Kontos March 6, 2026March 6, 2026

Jefferies maintained a Buy rating on Silence Therapeutics plc (SLN) on March 05, 2026. The SLN analyst rating was reiterated in a note saying the stock “looks cheap at $175M+ EV,” according to StreetInsider. The firm’s call arrived with a reported 7.0% ($0.36) price change since the note, and market participants should weigh valuation, clinical risk, and liquidity when sizing positions.